BBIO
BridgeBio Pharma, Inc.
NASDAQ · Healthcare · Biotechnology · US
$76.82
+3.77%Year over year
Reported trailing growth
- Revenue
- +167.3%
- EBITDA
- +34.9%
- EBIT
- +32.8%
- EPS
- +27.4%
- Free cash flow
- +37.1%
- Operating cash flow
- +36.9%
Forward estimates
Based on analyst estimates
- Revenue
- +54.3%
- EBITDA
- +71.0%
- EPS
- +45.7%
Three-year CAGR
- Revenue
- +86.3%
- EBITDA
- -54.9%
- EBIT
- +4.0%
- Net income
- -36.1%
- EPS
- -31.6%
- Free cash flow
- +14.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2026